Filing Flows › Neogenomics (NEO) › Q3 2025
Neogenomics (NEO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 28, 2025
Neogenomics (NEO) reported revenue of $188M for the third quarter 2025 (Q3 2025), +12% from a year earlier and +4% from the quarter before. Operating margin was -14.4%, net loss $27.1M (14.4% of revenue).
Neogenomics, Q3 2025: revenue $188M (+12% year over year), operating margin -14.4%, net loss $27.1M, operating cash flow $8.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $188M | +4% | +12% |
| Operating profit | −$27.0M | — | — |
| Net earnings | −$27.1M | — | — |
| Operating cash flow | $8.9M | -56% | -4% |
| Free cash flow | $570K | -96% | — |
What changed
Revenue was $187.8M in Q3 2025, up 12% year over year and up 4% from the previous quarter. Client direct billing was the largest line at 70% of revenue. Client direct billing added $10.6M year over year (up 9%), 53% of the total change. Self-pay declined 68%.
Gross margin was 42.8%, down 1.8 points from a year earlier. Operating costs exceeded revenue by $27.0M, an operating margin of -14.4%. Operating expenses grew 12% against revenue growth of 12%. The fastest-growing cost line was Other operating costs (+602%). The quarter ended with a net loss of $27.1M, narrower than the previous quarter's $45.1M loss.
Operating cash flow was $8.9M (down 4% year over year). Non-cash charges added back $16.4M of depreciation and amortization and $10.3M of share-based compensation. Working capital and other items added $9.3M. Capital expenditures of $8.3M left free cash flow of $570K.
Questions
What was Neogenomics' revenue in the third quarter 2025?
Neogenomics (NEO) reported revenue of $188M for the third quarter 2025 (Q3 2025), +12% from a year earlier and +4% from the quarter before.
Was Neogenomics profitable in the third quarter 2025?
Operating loss was $27.0M (-14.4% of revenue) and net loss $27.1M.
Source: Neogenomics 10-Q on SEC EDGAR.